Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 9/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 9/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 9/20 | 0.35 |
| ▸ | GABRP | O00591 | 6/20 | 0.35 |
| ▸ | GABRD | O14764 | 6/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 6/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 6/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 6/20 | 0.35 |
| ▸ | GABRE | P78334 | 6/20 | 0.35 |
| ▸ | GABRA6 | Q16445 | 6/20 | 0.35 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.35 |
| ▸ | GABRG3 | Q99928 | 6/20 | 0.35 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30439201 | 0.80 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2KDM4EPOLBGABRA2 | |
| SCHEMBL967220 | 0.80 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2KDM4EPOLBGABRA2 | |
| Hydrochloric Acid SCHEMBL29123267 | 0.78 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2KDM4EPOLBGABRA2 | |
| SCHEMBL18600038 | 0.77 | GABRP (0.36) | ALDH1A1SMN1; SMN2KDM4EPOLBGABRA2 | |
| Nitrogen SCHEMBL28714282 | 0.76 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2KDM4EPOLBGABRA2 | |
| SCHEMBL978300 | 0.75 | CA1 (0.44) | ALDH1A1SMN1; SMN2KDM4EPOLBGABRA2 | |
| SCHEMBL30777281 | 0.75 | CA1 (0.44) | ALDH1A1SMN1; SMN2KDM4EPOLBGABRA2 | |
| SCHEMBL18256224 | 0.74 | PDE2A (0.36) | ALDH1A1GABRA2GABRB2GABRB3GABRP | |
| SCHEMBL29746198 | 0.74 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2KDM4EPOLBGABRA2 | |
| SCHEMBL904486 | 0.74 | ALDH1A1 (0.48) | ALDH1A1SMN1; SMN2KDM4EPOLBGABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160075724-A1 | CETP Inhibitors | MERCK SHARP & DOHME (US) | 2016-03-17 | — | — | US | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8735435-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-1765793-B1 | ANACETRAPIB AND OTHER CETP INHIBITPRS | MERCK SHARP & DOHME (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2415759-A1 | CETP inhibitors | Merck Sharp & Dohme Corporation (US) | 2012-02-08 | — | — | EP | disclosed |
| CN-102311401-A | CETP INHIBITORS | MERCK & CO INC | 2012-01-11 | — | — | CN | disclosed |
| CN-102304096-A | CETP inhibitors | MERCK SHARP & DOHME | 2012-01-04 | — | — | CN | disclosed |
| US-20100099716-A1 | CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-22 | — | — | US | disclosed |
| US-7652049-B2 | 1-benzyl-4-[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]imidazolidin-2-one; cholesteryl ester transfer protein inhibitor; raising HDL-cholesterol, reducing LDL-cholesterol; atherosclerosis; antiinflammatory agent; synergistic mixture with other active ingredients | MERCK & CO., INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| US-20060040999-A1 | CETP inhibitors | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221383-A1 | CETP INHIBITORS | CETP, APOB, MTTP | ALDH1A1 3887/4885SMN1; SMN2 4859/4885KDM4E 1437/4885 |
| US-20060040999-A1 | CETP inhibitors | CETP, APOB, MTTP | ALDH1A1 3887/4885SMN1; SMN2 4859/4885KDM4E 1437/4885 |
| US-20080119476-A1 | Cetp Inhibitors | CETP, APOB, MTTP | ALDH1A1 3887/4885SMN1; SMN2 4859/4885KDM4E 1437/4885 |
| US-20100099716-A1 | CETP INHIBITORS | CETP, APOB, MTTP | ALDH1A1 3887/4885SMN1; SMN2 4859/4885KDM4E 1437/4885 |
| US-20160075724-A1 | CETP Inhibitors | CETP, APOB, MTTP | ALDH1A1 3887/4885SMN1; SMN2 4859/4885KDM4E 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.